Literature DB >> 19223634

Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1.

Kurt Van Baelen1, Karl Salzwedel, Evelien Rondelez, Veerle Van Eygen, Stephanie De Vos, Ann Verheyen, Kim Steegen, Yvan Verlinden, Graham P Allaway, Lieven J Stuyver.   

Abstract

In this study, we evaluated baseline susceptibility to bevirimat (BVM), the first in a new class of antiretroviral agents, maturation inhibitors. We evaluated susceptibility to BVM by complete gag genotypic and phenotypic testing of 20 patient-derived human immunodeficiency virus type 1 isolates and 20 site-directed mutants. We found that reduced BVM susceptibility was associated with naturally occurring polymorphisms at positions 6, 7, and 8 in Gag spacer peptide 1.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19223634      PMCID： PMC2681549          DOI： 10.1128/AAC.01650-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling.

Authors:  H Vermeiren; E Van Craenenbroeck; P Alen; L Bacheler; G Picchio; P Lecocq
Journal:  J Virol Methods       Date:  2007-06-15       Impact factor: 2.014

2.  3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro.

Authors:  Michael Sakalian; Curtis P McMurtrey; Frederick J Deeg; Christopher W Maloy; Feng Li; Carl T Wild; Karl Salzwedel
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  Determinants of activity of the HIV-1 maturation inhibitor PA-457.

Authors:  Feng Li; Dorian Zoumplis; Claudia Matallana; Nicole R Kilgore; Mary Reddick; Abdul S Yunus; Catherine S Adamson; Karl Salzwedel; David E Martin; Graham P Allaway; Eric O Freed; Carl T Wild
Journal:  Virology       Date:  2006-08-22       Impact factor: 3.616

4.  In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).

Authors:  Catherine S Adamson; Sherimay D Ablan; Ioana Boeras; Ritu Goila-Gaur; Ferri Soheilian; Kunio Nagashima; Feng Li; Karl Salzwedel; Michael Sakalian; Carl T Wild; Eric O Freed
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

Review 5.  Maturation inhibitors: a new therapeutic class targets the virus structure.

Authors:  Karl Salzwedel; David E Martin; Michael Sakalian
Journal:  AIDS Rev       Date:  2007 Jul-Sep       Impact factor: 2.500

6.  PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.

Authors:  F Li; R Goila-Gaur; K Salzwedel; N R Kilgore; M Reddick; C Matallana; A Castillo; D Zoumplis; D E Martin; J M Orenstein; G P Allaway; E O Freed; C T Wild
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-22       Impact factor: 11.205

7.  Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.

Authors:  Patrick F Smith; Abayomi Ogundele; Alan Forrest; John Wilton; Karl Salzwedel; Judy Doto; Graham P Allaway; David E Martin
Journal:  Antimicrob Agents Chemother       Date:  2007-07-16       Impact factor: 5.191

8.  Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation.

Authors:  Jing Zhou; Xiong Yuan; David Dismuke; Brett M Forshey; Christopher Lundquist; Kuo-Hsiung Lee; Christopher Aiken; Chin Ho Chen
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103
  8 in total
  44 in total

1.  Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice.

Authors:  Juan Fontana; Paul W Keller; Emiko Urano; Sherimay D Ablan; Alasdair C Steven; Eric O Freed
Journal:  J Virol       Date:  2015-11-04       Impact factor: 5.103

2.  MicroED structures of HIV-1 Gag CTD-SP1 reveal binding interactions with the maturation inhibitor bevirimat.

Authors:  Michael D Purdy; Dan Shi; Jakub Chrustowicz; Johan Hattne; Tamir Gonen; Mark Yeager
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-10       Impact factor: 11.205

Review 3.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

Review 4.  HIV type 1 Gag as a target for antiviral therapy.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-21       Impact factor: 2.205

5.  Second Generation Inhibitors of HIV-1 Maturation.

Authors:  Alicia Regueiro-Ren; Ira B Dicker; Umesh Hanumegowda; Nicholas A Meanwell
Journal:  ACS Med Chem Lett       Date:  2019-02-08       Impact factor: 4.345

6.  Resistance to Second-Generation HIV-1 Maturation Inhibitors.

Authors:  Emiko Urano; Uddhav Timilsina; Justin A Kaplan; Sherimay Ablan; Dibya Ghimire; Phuong Pham; Nishani Kuruppu; Rebecca Mandt; Stewart R Durell; Theodore J Nitz; David E Martin; Carl T Wild; Ritu Gaur; Eric O Freed
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

7.  Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants.

Authors:  Zhao Dang; Keduo Qian; Phong Ho; Lei Zhu; Kuo-Hsiung Lee; Li Huang; Chin-Ho Chen
Journal:  Bioorg Med Chem Lett       Date:  2012-07-03       Impact factor: 2.823

Review 8.  HIV-1 Capsid Inhibitors as Antiretroviral Agents.

Authors:  Suzie Thenin-Houssier; Susana T Valente
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

9.  Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat.

Authors:  Catherine S Adamson; Michael Sakalian; Karl Salzwedel; Eric O Freed
Journal:  Retrovirology       Date:  2010-04-20       Impact factor: 4.602

Review 10.  Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

Authors:  Martin Stürmer; Hans Wilhelm Doerr; Lutz Gürtler
Journal:  Med Microbiol Immunol       Date:  2009-06-04       Impact factor: 3.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.